Warfarin vs Aspirin in Reduced Ejection Fraction -STAT

华法林与阿司匹林在射血分数降低方面的比较 -STAT

• 批准号: 7430249
• 负责人: JOHN L THOMPSON
• 金额: $ 20万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7430249
• 关键词: Address; African American; Algorithms; Anticoagulation; Aspirin; Atrial Fibrillation; Cardiac; Cerebral hemisphere hemorrhage; Cerebrum; Cessation of life; Chronic; Class; Clinical; Clinical Trials; Clinical Trials, Other; Communication; Data; Double-Blind Method; EFRAC; End Point; Enrollment; Ensure; Equilibrium; Etiology; Fibrinolytic Agents; Functional disorder; Goals; Heart Diseases; Heart failure; Infarction; International Normalized Ratio; Intervention; Ischemic Stroke; Left; Left Ventricular Ejection Fraction; Link; Medication Management; Multi-Institutional Clinical Trial; Myocardial Infarction; Myocardial Ischemia; Operative Surgical Procedures; Patients; Principal Investigator; Protocols documentation; Quality Control; Randomized; Range; Rate; Relative (related person); Relative Risks; Reporting; Research; Research Personnel; Risk; Risk Reduction; Safety; Side; Specific qualifier value; Stroke; Subgroup; Testing; Time; To specify; Upper arm; Ventricular; Warfarin; Woman; clinical research site; cognitive function; data management; day; design; experience; follow-up; hazard; men; mortality; patient safety; prevent; size

WARCEF-STAT and WARCEF-CLIN are two separate but highly coordinated units which together constitute WARCEF, a two-arm (1:1) double-blind randomized multicenter clinical trial (target enrollment 2860 patients at 70 clinical sites) designed to test the primary null hypothesis of no difference between warfarin (INR 2.5-3, target 2.75) and aspirin (325 mg/day) in 3-5 year survival for the composite endpoint death or stroke or intracerebral hemorrhage among patients with low (<=30%) cardiac Left Ventricular Ejection Fraction (LVEF). Prespecified secondary hypotheses are tested for subgroups of women and African Americans, and for the endpoint of stroke alone. Prespecified tertiary hypotheses are tested by amalgamating data from WARCEF and another trial (WATCH). The goals of WARCEF-STAT are: 1) to conduct, efficiently integrate, and be responsible for all WARCEF data management, double-blinding, medication management, quality control, and reporting operations. 2) to specify, conduct and be responsible for all interim, safety, and final statistical analyses for WARCEF and for the reporting of these results. 3) to transmit to the Clinical Coordinating Center (CCC) in a timely fashion all of the data which the principal investigator of WARCEF-CLIN needs to meet his responsibilities in terms of ensuring patient safety and directing all clinical operations. Goal 1 is accomplished by integrating a Data Management Center with substantial experience in cardiac trials and an anticoagulation unit which is successfully conducting an ongoing double blind warfarin-aspirin study (WARSS). The double-blind algorithm used in WARSS to fabricate INRs for patients on active aspirin will be recalibrated and revalidated for the WARCEF target range before WARCEF begins. Goal 2 is achieved by a statistical analysis unit that is experienced in stroke, cardiac, and other clinical trials. Goal 3 is ensured by an Operations Committee of WARCEF-STAT and WARCEF-CLIN investigators and senior coordinators which meets frequently under tightly specified and controlled communication protocols.

WARCEF- stat和WARCEF- clin是两个独立但高度协调的单位，它们共同构成WARCEF。